Plain-English translation of NCT05776524 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Pancreatic Cancer research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a combination treatment for advanced pancreatic cancer that has spread beyond the pancreas. Patients will receive two standard chemotherapy drugs — and nab-paclitaxel — along with a new device called the TheraBionic device that delivers special electromagnetic fields to the body. The research team wants to see if adding this electromagnetic treatment to the chemotherapy helps patients live longer and keeps their cancer from growing.
Pancreatic cancer that has spread is very serious and current treatments don't work well enough for many patients. This trial is exploring whether the electromagnetic device, when combined with existing chemotherapy, might improve survival rates and help control the cancer better.
You likely qualify if…
You likely don't qualify if…
You would receive the standard chemotherapy drugs intravenously along with treatment from the TheraBionic device, which delivers electromagnetic fields to your body. You would have regular visits to the clinic for chemotherapy infusions, device treatment, and monitoring of your health and how well the cancer is responding. The study will follow your progress for at least 6 months to measure whether the combination treatment helps you live longer and controls your cancer.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
United States